AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06262854 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Calcium-sulphate granules with tobramicina+vancomicina
Description: Local calcium-sulphate antibiotics deliver for the treatment of diabetic foot osteomyelitis
Study NCT05877222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daridorexant 10 mg
Description: Daridorexant will be available as film-coated tablets for oral administration formulated at strengths of 10 mg.
Study NCT05877222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daridorexant 25 mg
Description: Daridorexant will be available as film-coated tablets for oral administration formulated at strengths of 25 mg.
Study NCT05235399 — intervention group
Intervention type: OTHER
Intervention: Echo scans
Description: Echo heart scan will be performed on the participating preterm infants on the 5th and 9th day of postnatal life.
Study NCT05912803 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simulated Equestrian Therapy
Description: The treatment group will receive Simulated Equestrian Therapy for 12 weeks thrice per week using 2 horse simulators (wooden and mechanical) in two phases.~Phase I The child will be instructed to ride the mechanical simulator in a pre-defined area measuring 10 yards and complete a total of 4 rounds of this area. Rest periods in between and after will be provided to the child when required. Major muscles of the body will be targeted here to strengthen the core.~Phase II The child will be instructed to ride the wooden simulator and a combination of goal directed activates will be performed.
Study NCT05912803 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neuro-Motor Therapy
Description: This group will perform overall stability and body balancing exercises to strengthen the core and develop the coordination and balance required for task performance. Each activity will be performed in a set of 2-3, considering the activity level of the child, with 8-12 repetitions attaining the available ROM and flexibility of the child. The participants will undergo warm-up before the exercise and cool-down afterwards.
Study NCT05241782 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: auricular acupressure
Description: Auricular therapy, as defined by Oleson, refers to a healthcare modality by stimulating the external surface of the ear to alleviate pathological conditions in other parts of the bodyExperimental group will receive acupressure treatment by the second week, trice daily, 3\~5minutes each session for a course of four weeks
Study NCT05992623 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zoll external defibrillator
Description: Patients with AF will be randomized to receive a full output synchronized 200J shock using a RBW waveform from a Zoll defibrillator
Study NCT05992623 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lifepak external defibrillator
Description: Patients with AF will be randomized to receive a full output synchronized 360J shock using a BTE waveform from a Lifepak defibrillator
Study NCT05397496 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PIT565
Description: Intravenous (i.v.) infusion or Subcutaneous (s.c.) injection
Study NCT06558227 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZG005 for Injection
Description: 10 mg/kg or 20 mg/kg administered intravenously Q3w
Study NCT06558227 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg administered intravenously Q3w
Study NCT06558227 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 200 mg administered intravenously Q3w
Study NCT05604131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deferiprone Tablets
Description: Deferiprone tablets are the active medication for the active arm of the study groups. Randomization will be done by investigational drug services pharmacist and intervention will be double-blinded to investigators and patients.
Study NCT05604131 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Deferiprone placebo is the non-medicated formulation for a control arm of the study groups.
Study NCT06147076 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Support Network Counseling Intervention
Description: Social support counseling intervention for kidney transplant candidates along with their social support networks.
Study NCT05638087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone Oral Suspension
Study NCT05638087 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: Placebo Oral Mix
Study NCT05937347 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU + UP4H
Description: Group treatment protocol of 8 weeks (approximately 105 minutes per week, 75 of face-to-face and 30 of virtual intervention).
Study NCT05937347 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU + M4H
Description: Group treatment protocol of 8 weekly 75 minute sessions (face-to-face intervention).
Study NCT05937347 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU + CT
Description: Group treatment protocol of 8 weekly 60 minutes sessions (virtual intervention).
Study NCT05937347 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: Standard pharmacological treatment usually provided to children with ADHD.
Study NCT05775562 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Pre and post dive examinations
Description: Performing pre-dive examinations:~- EFR by plethysmography cabin~Realization of the examinations the day of the dive:~* Portable Spirometry~* Pulmonary ultrasound~* Cardiac ultrasound~* Measurement of circulating bubbles~* ECG~* Venous blood sampling (biological collection)~* Water balance (Δweight/water intake)~* EFR by plethysmography cabin~* Weight measurement~Realization of the examinations the day after the dive:~* Venous blood sample (biological collection)~* Portable Spirometry~* Pulmonary ultrasound~* Cardiac ultrasound~* Weight measurement
Study NCT05928286 — intervention group
Intervention type: DRUG
Intervention: Remaxol
Description: The perioperative infusion of Remaxol® (Inosine + Meglumine + Methionine + Nicotinamide + Succinic acid)
Study NCT05838196 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Point-of-care ultrasound
Description: Point-of-care ultrasound performed during clinic appointment
Study NCT04723147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa Levodopa
Description: Patients will receive L-DOPA at doses ranging from 150 to 450 mg administered at a ratio of 1 mg carbidopa for every 4 mg L-DOPA. Starting dose is 150 mg/day with dose escalation 150 mg/day per week to a final dose of 450 mg/day
Study NCT04723147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A placebo is a sugar pill that has no therapeutic effect and will be administered orally. Participants will receive 1 placebo tablet matching the Carbidopa Levodopa tablet.
Study NCT05608902 — intervention group
Intervention type: OTHER
Intervention: Dynamic full-field optical coherence tomography analysis of skin biopsy or resection
Description: Dynamic full-field optical coherence tomography analysis of skin biopsy or resection in the dermatology department before conventional histopathological analysis
Study NCT05503563 — intervention group
Intervention type: PROCEDURE
Intervention: terta modal bladder preservation
Description: neoadjuvant chemotherapy, partial cystectomy, radiotherapy
Study NCT06279871 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARCT-2303
Description: Self-Amplifying RNA COVID-19 vaccine (Omicron XBB.1.5)
Study NCT06279871 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ARCT-2303
Description: Self-Amplifying RNA COVID-19 vaccine (Omicron XBB.1.5)
Study NCT06279871 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Description: Licensed cell-based influenza vaccine
Study NCT06279871 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza vaccine
Description: Licensed cell-based influenza vaccine
Study NCT06279871 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine, adjuvanted
Description: Licensed influenza vaccine, adjuvanted
Study NCT06279871 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza vaccine, adjuvanted
Description: Licensed influenza vaccine, adjuvanted
Study NCT06279871 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% saline
Study NCT06279871 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 0.9% saline
Study NCT06655610 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: External Trigeminal Nerve Stimulation
Description: Active eTNS will be provided by applying single, bipolar pulses of 0.5 milliseconds duration at a frequency of 125 hertz, with an active period of 30 seconds on/off. Stimulation current will range from 0.2 mili ampere (mA) to 10 mA. The level of current, which is noticeable, yet within the level of comfort, will be identified for each patient by titration at baseline. Depending on the perception of stimulation, the level of current may be altered during the four weeks of treatment, by either the guardian or adolescent in control of the settings.
Study NCT06655610 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham device
Description: The stimulator and patches will be identical in appearance to the active treatment. The guardian/the adolescent will be informed to administer the device in the same fashion as with active treatment. The sham device will however be programmed to only apply stimulation for 30 seconds every hour during sleep, optimally at a frequency of maximum 2 Hz. As with the active eTNS, the sham stimulation current will range from 0.2 to 10 mA. Such settings have previously been considered to induce the sensation of a current applied to the forehead as seen with active treatment, yet without it being therapeutically effective. Stimulation will be directed through an internal resister, which ensures draining of batteries and need for recharging after each session. The manufacture of the eTNS device (Neurosigma) will oversee the programming the sham device.
Study NCT05319028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mivavotinib
Description: oral tablet
Study NCT06734910 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HealthyPregnancy
Description: A digital care guide comprising of:~1. Information about diet, exercise and mental wellbeing in pregnancy. Presented in text, video and audio material featuring various healthcare professionals.~2. Online exercise. Access to live online structured physical exercise twice a week and to an off line library of exercise videos.~3. Chat function with possibility to chat safely with healthcare professionals.~4. Push-notifications reminding the participants of upcoming antenatal appointments.~In addition an invitation to monthly café sessions focusing on e.g., mental health, parenting skills, breastfeeding and healthy lifestyle.
Study NCT06736418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 225Ac-ABD147
Description: A delta-like ligand 3 (DLL3)-targeting antibody fragment conjugated with a linker-chelator that effectively coordinates Ac-225
Study NCT06736184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Zirconium Cyclosilicate (SZC)
Description: 5g/meal\*3meals/day
Study NCT06735755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEAM-301: Single dose of BEAM-301 administered by IV
Description: BEAM-301 is designed to correct the G6PC1 c.247C>T allele via an A:T-to-G:C base-pair substitution, resulting in restoration of G6Pase-α catalytic activity.
Study NCT06735781 — intervention group
Intervention type: DRUG
Intervention: Nivolumab
Description: As prescribed by the treating clinician
Study NCT05406752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol Uniflash (125 mg/ 1.25 mL)
Description: Oromucosal solution (125 mg/ 1.25 mL) for buccal route
Study NCT05930782 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piperaquine Phosphate
Description: PQP hard tablet 320 mg; single dose (320 mg) given orally with 240 ml of water
Study NCT05930782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperaquine Phosphate
Description: PQP dispersible granules 320 mg dose equivalent dispersed in 25 ml of water; single dose (320 mg) given orally
Study NCT05280951 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Focused-PPC Care
Description: Individual clinical assessments and counseling for each group member will last about 15 minutes. Then, there will be 1 hour of group time dedicated to education and support. Each group session will be led by two trained and registered midwives who will provide both clinical care, education, and support as needed. In addition, each group session will be supported by a project assistant. Focused-PPC will be implemented in addition to newborn care.
Study NCT05280951 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Women in the control group will receive standard postnatal care (PNC) currently practiced in the health centers. This involves attending PNC visits at the health center within 14 days after birth, at 6 weeks, and monthly thereafter up to one year.
Study NCT05471908 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: As-needed follow up
Description: At hospital discharge, participant receives a recommendation for PRN follow-up. Recommendation informs participant that scheduling a follow-up visit is not needed at discharge and suggests that participant follow symptoms after discharge to decide if a visit is ultimately needed or not.
Study NCT05471908 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Automatic follow-up
Description: At hospital discharge, participant receives a recommendation for automatic follow-up. Recommendation instructs participant to schedule a follow-up visit and attend the visit even if symptoms get better.
Study NCT06491407 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Chewing and swallowing performance assessment and related factors
Description: In the study, the dependent variables, chewing performance, will be evaluated with the Chewing and Swallowing Test of Solids, and swallowing performance will be assessed with the Repetitive Saliva Swallowing Test and Dysphagia Limit. Independent variables affecting chewing and swallowing performance have been considered within the scope of the ICF, and all possible factors determined for both geriatrics and swallowing have been listed, and the evaluation parameters and assessment tools have been decided.
Study NCT05745675 — intervention group
Intervention type: DEVICE
Intervention: Pulse oximeter
Description: OLV-4202 pulse oximeter SW version: 01-15)
Study NCT05273957 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Case Manager
Description: Patients are followed up by a nurse specialist in parkinsonism (case manager) who interacts with the treating neurologist and a multidisciplinary team
Study NCT05273957 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard-of-care
Description: Patients are managed only by the neurologist according the institution's clinical practice
Study NCT05529823 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: warm shower
Description: A warm shower will be applied for 20 minutes to the pregnant woman whose cervical dilatation reaches 4-5 cm and 7-8 cm.
Study NCT05111847 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Baseplates with two types of adhesives are tested: 3M 1522 & Nitto ST-2410WD
Description: Baseplates with two different types of adhesives are placed behind the ears; One baseplate with one of the two types of the adhesive behind each ear
Study NCT05111847 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Baseplates with two types of adhesives are tested: Amparo 130002 & 3M 2480
Description: Baseplates with two different types of adhesives are placed behind the ears; One baseplate with one of the two types of the adhesive behind each ear
Study NCT05146362 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vermont RETAIN
Description: RETAIN projects include a combination of medical provider services, stay-at-work/return-to-work (SAW/RTW) coordination services, and other SAW/RTW services. The evaluation compares the treatment group that is eligible to receive the full set of RETAIN intervention activities and a control group that is not.
Study NCT04906616 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mlambe
Description: A combined economic and relationship-strengthening intervention at the couple level to redirect funds spent on alcohol into financial investments (e.g., education, income-generating business) and to improve couple relationships and adherence to ART.
Study NCT06512272 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Video recorded shared using a mobile application
Description: The routine hospital discharge explanation is video recorded \[up to three minutes\].~The video is uploaded by to a mobile app for the patient and patient/ relatives can review the advice multiple times
Study NCT03963453 — intervention group
Intervention type: OTHER
Intervention: Physical Exercise
Description: Physical exercise are prescribed to be performed three times per week for a year
Study NCT06018272 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mentalization-Based Treatment (MBT)
Description: Patients in MBT will receive a maximum of 58 sessions in total. Of those, 30 are weekly individual sessions. 28 sessions are weekly group sessions conducted by two therapists, and consisting of 8 introductory sessions of group psychoeducation followed by 20 group therapy sessions. The duration of MBT is 12 months. MBT is manualized and relies on validating the emotional experience of patients that aims to promote mentalizing. The proposed mechanism of change in MBT is to stabilize mentalizing in certain focus areas in order to create a psychic buffer between affect and behaviour to foster affect regulation, reduce impulsivity and promote functional supportive relationships.
Study NCT06018272 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bona-Fide Treatment in Germany (BFT)
Description: Patients in BFT will receive one to two weekly sessions of Bona-Fide-Treatment (Psychodynamic Therapy, PT, or Cognitive Behavioural Therapy, CBT) conducted by community experts delivered as short-term psychotherapy (\<24 sessions) or long-term psychotherapy (>24 sessions). BFT can be delivered as individual, group or a combination of individual and group treatment as stated in the German psychotherapy regulations.
Study NCT06518681 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PoliaValve (Aortic)
Description: Aortic Valve Replacement
Study NCT05304065 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SAFETY-A within usual ED Care
Description: SAFETY-A is a single session collaborative, strengths-based, developmentally nuanced, cognitive-behavioral intervention (CBT) to increase safety and mental health treatment initiation. The therapist works with the youth and family (or significant other, SO) separately and together to build hope and reasons for living, develop a personal safety plan, increase protective supports; and increase motivation for and linkage to treatment.
Study NCT05304065 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Combined SAFETY-A within usual ED Care + CLASP Therapeutic Follow-Up Contacts
Description: COMB, includes SAFETY-A within usual ED care plus CLASP therapeutic and caring follow-up contacts designed to strengthen safety and treatment initiation and engagement. Core functions of CLASP include: building hope/reducing hopelessness; enhancing social/family support; strengthening problem-solving; and increasing treatment initiation and engagement.
Study NCT05667285 — intervention group
Intervention type: DEVICE
Intervention: BIOTRONIK Orsiro Sirolimus-Eluting Coronary Stent System
Description: During the procedure, the investigator assesses the arterial diameter and lesion length either visually or using QCA to select the appropriate stent. The number of stents required for each lesion is determined by the investigator based on the specific circumstances. The length of the stent should cover from the proximal normal reference vessel to the distal normal reference vessel, ensuring complete coverage of the lesion.~The number of stents required for each lesion is determined by the investigator based on the specific circumstances. If the first stent does not fully cover the lesion, a second or even more stents may be used. In such cases, the second or additional stents are selected by the investigator based on the specific circumstances, such as using Orsiro SES stents, unless clinically contraindicated or specifically required. Please refer to the stent's Instructions for Use for the procedure.~If stent overlap occurs, the overlapping part should be at least 2mm.
Study NCT06519773 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified periosteal inhibition
Description: After local anathesia, a traumatic extraction of the hopeless tooth will be made trying as much as possible to preserve the labial plate of bone and overlying soft tissue.~* Once the tooth is extracted, the socket is gently debrided and irrigated using sterile saline solution. Then the dental implant provided by Auto Fit Dental Implant is placed in the best prosthetic driven position, following the guidelines for immediate implants using prefabricated computer guided surgical template.~* After accurate implant placement, a full-thickness flap will be elevated at mesial and distal papilla making a buccal envelope. A bone lamina and provided by GRANNTIE 1 mm thickness will be trimmed and hydrated in sterile saline solution for 30 s to soften it; it should be 1-2 mm larger and deeper than the vestibular bone.